Table 3.

Studies indicating no difference in the sensitivity of the diabetic heart to ischemic injury compared to normoglycemic controls.

Study	Model	Ischemic Protocol	Duration/onset of diabetes	Substrates	Model of diabetes	End points
Hadour et al. (1998) [48]	Rabbit, 10% glucose infusion to 300 mg/dL blood glucose	In vivo nonrecovery, 30 min regional ischemia/3 hr reperfusion	Blood glucose maintained at 300 mg/dL throughout procedure	In vivo substrates	Type I diabetes	Infarction
Tanaka et al. (2002) [62]	Dog, alloxan (40 mg/kg) and STZ (25 mg/kg)	In vivo nonrecovery, 60 min regional ischemia/3 hr reperfusion	3 weeks	In vivo substrates	Type I diabetes	Infarction
Ravingerová et al. (2003) [53]	Rat, STZ (45 mg/kg)	In vivo nonrecovery, 30 min regional ischemia/4 hr reperfusion	8 weeks	In vivo substrates	Type I diabetes	Infarction
Ebel et al. (2003) [31]	Rabbit- alloxan (100 mg/kg)	In vivo nonrecovery, 30 min regional ischemia/2 hr reperfusion	6 weeks	In vivo substrates	Type I diabetes	Infarction
Desrois et al. (2004) [63]	Aged Goto Kakisaki Rat, male	Langendorff isolated heart, 32 min low flow global ischemia/32 min reperfusion	In bred strain	11 mmol/L glucose	Type II diabetes	Myocardial function
Ma et al. (2006) [56]	Rat, STZ (50 mg/kg)	In vivo nonrecovery, 30 min regional ischemia/2 hr reperfusion	6 weeks	In vivo substrates	Type I diabetes	Infarction
Bulhak et al. (2009) [64]	Goto Kakizaki Rat, male	In vivo nonrecovery, 35 min regional ischemia/2 hr reperfusion	In bred strain	In vivo substrates	Type II diabetes	Infarction
Matsumoto et al. (2009) [65]	Goto Kakizaki Rat, male	In vivo nonrecovery, 30 min regional ischemia/2 hr reperfusion	In bred strain	In vivo substrates	Type II diabetes	Infarction
Shi-Ting et al. (2011) [58]	Rat, STZ (60 mg/kg)	Langendorff isolated heart, 30 min regional ischemia/40 min reperfusion	8 weeks	11 mmol/L glucose	Type I diabetes	Infarction and creatine kinase release